Why the study?
Few reports have demonstrated that bradycardia occurs when amiodarone is used in combination with sofosbuvir.
The combination of sofosbuvir and amiodarone can cause severe, life-threatening bradycardia, likely due to P-glycoprotein inhibition by amiodarone increasing sofosbuvir concentrations in cardiomyocytes.
Supports vigilance for bradycardia with amiodarone-sofosbuvir co-use; hypothesis-generating and requires validation.
Amiodarone, prescribed for cardiac conditions, including dysrhythmia, is associated with bradycardia. However, few reports have demonstrated that bradycardia is observed when amiodarone is used in combination with sofosbuvir, a direct-acting antiviral drug for chronic hepatitis C. We herein report the case of a male patient in his 70s with chronic atrial fibrillation and prostatic hyperplasia and was also taking amiodarone, who experienced severe bradycardia and syncope a day after taking sofosbuvir and ribavirin for chronic hepatitis C. After discontinuing amiodarone, ribavirin, and sofosbuvir, bradycardia did not recur. Therefore, we must consider drug interactions between amiodarone and sofosbuvir in patients with severe bradycardia.
No takes yet. Share an insight, caveat, or question.
Monoe et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: